Tumor drug screening for research

Tumor drug screening, also known as anti-cancer drug screening or cancer drug testing, refers to the process of examining various drugs to identify those that can effectively treat tumors. This screening is undertaken to uncover potential therapeutic options for cancer patients. It plays a crucial role in the development of new medications and the enhancement of existing treatments.

The primary goal of tumor drug screening is to identify compounds that can selectively inhibit the growth or kill cancer cells while sparing healthy cells. This approach, known as targeted therapy, aims to maximize treatment efficacy while minimizing side effects. Screening involves subjecting cancer cells, typically sourced from tumor samples to a wide range of drugs to determine their potential effectiveness in killing cancer cells.

Various techniques are employed in tumor drug screening, such as high-throughput screening, which allows for the rapid testing of thousands of compounds. This method enables researchers to identify promising candidates that can then undergo further evaluation for their effectiveness, safety, and potential clinical applications.

MingCeler provides a full range of high-quality preclinical development services for oncology drug screening and validation, including target identification and validation, in vitro cellular assays and screening, in vivo tumor model construction, in vivo pharmacology, pharmacokinetics, pharmacodynamic and basic toxicology assessment.

Depending on the needs of our clients, we can provide deeper mechanistic studies.